Olanzapine (Zyprexa Relprevv) vs Quetiapine (Seroquel XR)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Olanzapine (Zyprexa Relprevv)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00088478 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.
Reported efficacy
Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)
Result source: NCT00088478
Quetiapine (Seroquel XR)
Marketed by Cheplapharm Arzneimittel GmbH and partners
NCT00640601 · Phase 3 · completed
This was a nonrandomized, single-group, open-label study of 295 treated participants, without a placebo or active comparator. Although 56.88% were reported to have improved clinical benefit on the primary CGI-CB measure, the uncontrolled design cannot determine how much of the improvement was due to quetiapine rather than other factors.
Next expected readout: February 2032 · NCT07152184 (registry estimate)
Reported efficacy
Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8) (not_applicable)
Result source: NCT00640601
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olanzapine (Zyprexa Relprevv) | Quetiapine (Seroquel XR) |
|---|---|---|
| PANSS total, change | —Not posted · NCT00088491 | -24 vs -15.9−8.1 vs placeboNCT018103801 other result
|
| CGI-S, change | -0.4 vs -0.3vs Oral OlanzapineNCT00320489 | -1.4 vs -0.9−0.5 vs placeboNCT018103801 other result
|
| PANSS response | —Not posted · NCT00088491 | 62.7% vs 32.1%+30.6 vs placeboNCT01810380 |
| PSP, change | —Not posted · NCT00088491 | 15.3 vs 9.4+5.9 vs placeboNCT01810380 |
| Relapse (% of patients) | 20.1% vs 18.5%vs Oral OlanzapineNCT00320489 | —Not posted · NCT00159770 |
PANSS total, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Quetiapine (Seroquel XR)
- -24 vs -15.9−8.1 vs placeboNCT01810380
1 other result
- 102.3 vs 100.5 NCT00640562
CGI-S, change
- Olanzapine (Zyprexa Relprevv)
- -0.4 vs -0.3vs Oral OlanzapineNCT00320489
- Quetiapine (Seroquel XR)
- -1.4 vs -0.9−0.5 vs placeboNCT01810380
1 other result
- -1.5 vs -1.0 NCT00640562
PANSS response
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Quetiapine (Seroquel XR)
- 62.7% vs 32.1%+30.6 vs placeboNCT01810380
PSP, change
- Olanzapine (Zyprexa Relprevv)
- —Not posted · NCT00088491
- Quetiapine (Seroquel XR)
- 15.3 vs 9.4+5.9 vs placeboNCT01810380
Relapse (% of patients)
- Olanzapine (Zyprexa Relprevv)
- 20.1% vs 18.5%vs Oral OlanzapineNCT00320489
- Quetiapine (Seroquel XR)
- —Not posted · NCT00159770
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Olanzapine (Zyprexa Relprevv): 9 of 9 rows · Quetiapine (Seroquel XR): 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olanzapine (Zyprexa Relprevv) Rows use multiple source trials | Quetiapine (Seroquel XR) Rows use multiple source trials |
|---|---|---|
| CGI-S absolute change · score No placebo or comparator arm | -0.17 score @ 313wka,b,c NCT00088465 · Phase 3 · registry result, not featured evidence | 0.51 score @ 24wka,b,c NCT00640601 · Phase 3 |
| PANSS General Psychopathology absolute change · score No placebo or comparator arm | 0.19 score @ 330wkd,a,b,e NCT00088465 · Phase 3 · registry result, not featured evidence | -13.2 score @ 8.14wkd,a,b,e NCT00779506 · Phase 4 · registry result, not featured evidence |
| PANSS Negative absolute change · score No placebo or comparator arm | -0.08 score @ 330wka,b,f NCT00088465 · Phase 3 · registry result, not featured evidence | 3.67 score @ 24wka,b,f NCT00640601 · Phase 3 |
| PANSS Positive absolute change · score No placebo or comparator arm | 0.21 score @ 330wka,b,f NCT00088465 · Phase 3 · registry result, not featured evidence | 2.36 score @ 24wka,b,f NCT00640601 · Phase 3 |
| PANSS Total absolute change · score No placebo or comparator arm | 0.3 score @ 330wka,b,f NCT00088465 · Phase 3 · registry result, not featured evidence | 10.95 score @ 24wka,b,f NCT00640601 · Phase 3 |
| Dropout rate | 54.9%g NCT00320489 · Phase 3 · monotherapy show 1 more result60.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 38%g NCT00640601 · Phase 3 show 7 more results16.5% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 20% NCT00954122 · Phase 4 · registry result, not featured evidence 30.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 20.8%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 9.8%g NCT00320489 · Phase 3 · monotherapy show 1 more result8.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 14.6%g NCT00640601 · Phase 3 show 7 more results7.3% NCT00640562 · Phase 3 —Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence —Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 4.2% NCT00779506 · Phase 4 · registry result, not featured evidence —Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence 2.6%Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 9.5%g NCT00320489 · Phase 3 · monotherapy show 1 more result18.3% NCT00088465 · Phase 3 · registry result, not featured evidence | 11.2%g NCT00640601 · Phase 3 show 7 more results3.7% NCT00640562 · Phase 3 0%Seroquel IR NCT01213836 · Phase 4 · registry result, not featured evidence 0%Seroquel XR NCT01213836 · Phase 4 · registry result, not featured evidence 2.9% NCT00954122 · Phase 4 · registry result, not featured evidence 0% NCT00779506 · Phase 4 · registry result, not featured evidence 1.3%Quetiapine NCT01810380 · Phase 3 · registry result, not featured evidence —Quetiapine Extended Release NCT01810380 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | show 1 more resultweight increased 14.4% anxiety 9.7% insomnia 9.7% NCT00088465 · Phase 3 · registry result, not featured evidence | show 5 more resultssomnolence 3.2% delusion 1.6% dizziness 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence psychotic disorder 1.6% sedation 1.6% sleep disorder 1.6% NCT01213836 · Phase 4 · registry result, not featured evidence constipation 25.5% insomnia 23.4% sedation 12.8% NCT00779506 · Phase 4 · registry result, not featured evidence somnolence 22.2% (placebo 5%) weight increased 13.1% (placebo 3.7%) dizziness 11.8% (placebo 0.6%) NCT01810380 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 24 weeks versus 313 weeks.
- dTrial phases differ: Phase 4 versus Phase 3.
- eAssessment timepoints differ: 8.14 weeks versus 330 weeks.
- fAssessment timepoints differ: 24 weeks versus 330 weeks.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olanzapine (Zyprexa Relprevv)
+ 9 further endpoints in the CSV export.
Quetiapine (Seroquel XR)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 16 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Quetiapine (Seroquel XR)'s landscape